BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 15810878)

  • 1. The radionuclide molecular imaging and therapy of neuroendocrine tumors.
    Li S; Beheshti M
    Curr Cancer Drug Targets; 2005 Mar; 5(2):139-48. PubMed ID: 15810878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of neuroendocrine tumors.
    Rufini V; Calcagni ML; Baum RP
    Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
    Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
    J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular imaging of neuroendocrine tumors.
    Carrasquillo JA; Chen CC
    Semin Oncol; 2010 Dec; 37(6):662-79. PubMed ID: 21167384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?
    Santhanam P; Chandramahanti S; Kroiss A; Yu R; Ruszniewski P; Kumar R; Taïeb D
    Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1144-55. PubMed ID: 25771906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
    Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
    J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.
    Kjaer A; Knigge U
    Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NEN - the role of somatostatin receptor scintigraphy in clinical setting.
    Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A
    Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
    Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview.
    Warner RR; O'dorisio TM
    Semin Nucl Med; 2002 Apr; 32(2):79-83. PubMed ID: 11965602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear imaging of neuroendocrine tumours.
    Sundin A; Garske U; Orlefors H
    Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraoperative use of gamma-detecting probes to localize neuroendocrine tumors.
    Adams S; Baum RP
    Q J Nucl Med; 2000 Mar; 44(1):59-67. PubMed ID: 10932602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
    Shapiro B
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.
    Ito T; Jensen RT
    Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):15-24. PubMed ID: 27875420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiopeptide imaging and therapy in Europe.
    Ambrosini V; Fani M; Fanti S; Forrer F; Maecke HR
    J Nucl Med; 2011 Dec; 52 Suppl 2():42S-55S. PubMed ID: 22144555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroblastoma and other neuroendocrine tumors.
    Howman-Giles R; Shaw PJ; Uren RF; Chung DK
    Semin Nucl Med; 2007 Jul; 37(4):286-302. PubMed ID: 17544628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.